Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Strong Tower Advisory Services

Strong Tower Advisory Services grew its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 70.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,554 shares of the company's stock after purchasing an additional 17,563 shares during the quarter. Strong Tower Advisory Services' holdings in Novo Nordisk A/S were worth $2,708,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Cox Capital Mgt LLC increased its stake in shares of Novo Nordisk A/S by 80.6% in the 1st quarter. Cox Capital Mgt LLC now owns 25,455 shares of the company's stock worth $1,768,000 after acquiring an additional 11,363 shares in the last quarter. NBC Securities Inc. boosted its holdings in shares of Novo Nordisk A/S by 79,440.0% during the 1st quarter. NBC Securities Inc. now owns 7,954 shares of the company's stock valued at $552,000 after acquiring an additional 7,944 shares during the last quarter. Baker Tilly Wealth Management LLC boosted its holdings in shares of Novo Nordisk A/S by 52.1% during the 1st quarter. Baker Tilly Wealth Management LLC now owns 12,799 shares of the company's stock valued at $889,000 after acquiring an additional 4,383 shares during the last quarter. Talbot Financial LLC boosted its holdings in shares of Novo Nordisk A/S by 115.5% during the 1st quarter. Talbot Financial LLC now owns 101,840 shares of the company's stock valued at $7,072,000 after acquiring an additional 54,574 shares during the last quarter. Finally, 180 Wealth Advisors LLC boosted its holdings in shares of Novo Nordisk A/S by 3.6% during the 1st quarter. 180 Wealth Advisors LLC now owns 5,014 shares of the company's stock valued at $348,000 after acquiring an additional 173 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price objective (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, BNP Paribas started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $128.00.

Novo Nordisk A/S Stock Up 1.3%

NVO stock traded up $0.95 during mid-day trading on Thursday, reaching $72.99. The company had a trading volume of 2,489,568 shares, compared to its average volume of 6,849,208. The company has a market capitalization of $327.54 billion, a price-to-earnings ratio of 22.19, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm has a fifty day simple moving average of $65.67 and a 200 day simple moving average of $81.09.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The company had revenue of $11.87 billion for the quarter. Analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.